Montelukast in childhood asthma: What is the evidence for its use?

Expert Review of Respiratory Medicine

Volumn 5, Issue 1, 2011, Pages 17-25

  Amlani, Salima ^a   McIvor, R Andrew ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

asthma; childhood; leukotrienes; montelukast; preschool

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; DIGOXIN; FLUTICASONE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PHENYTOIN; PLACEBO; SALMETEROL; THEOPHYLLINE; WARFARIN; ZAFIRLUKAST;

ABDOMINAL PAIN; ADD ON THERAPY; ADRENAL SUPPRESSION; ADVERSE OUTCOME; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHMA; BRONCHOSPASM; CELL ACTIVATION; CHEMICAL STRUCTURE; COUGHING; DISEASE EXACERBATION; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPHONIA; EAR INFECTION; EVENING DOSAGE; FORCED EXPIRATORY VOLUME; GROWTH RETARDATION; HEADACHE; HUMAN; HYPOGLYCEMIA; INFLAMMATORY CELL; MAXIMUM PLASMA CONCENTRATION; MEDIATOR RELEASE; MONOTHERAPY; MORNING DOSAGE; NAUSEA; OROPHARYNX CANDIDIASIS; PATIENT CARE; PHARYNGITIS; POSTMARKETING SURVEILLANCE; PREVALENCE; QUALITY OF LIFE; RESPIRATORY TRACT MUCOSA; SIDE EFFECT; THROAT IRRITATION; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 79952149705     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.10.90     Document Type: Article

References (58)

1. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N. Engl. J. Med. 323, 645-655 (1990). (Pubitemid 20280195)
2. Holgate ST, Frew AJ. Choosing therapy for childhood asthma. N. Engl. J. Med. 337, 1690-1692 (1997). (Pubitemid 27510111)
3. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N. Engl. J. Med. 323, 645-655 (1990). (Pubitemid 20280195)
4. Lougheed DM, Lemiere C, Dell SD et al. Canadian Thoracic Society asthma continuum - 2010 consensus summary for children six years of age and over, and adults. Can. Respir. J. 17(1), 15-24 (2010).
5. Kovesi T, Schuh S, Spier S et al. Achieving control of asthma in preschoolers. Can. Med. Assoc. 18(4), 173-182 (2010).
6. To T, Dell S, Dick PT et al. Case verification of children with asthma in Ontario. Pediatr. Allergy Immunol. 17, 69-76 (2006).
7. Martinez FD. Trends in asthma prevalence, admission rates and asthma deaths. Respir. Care 53, 561-565 (2008).
8. Harmanci K. Montelukast: its role in the treatment of childhood asthma. Ther. Clin. Risk Man. 3(5), 885-892 (2007). (Pubitemid 350162087)
9. Wright AL, Taussig LM. Lessons from long term cohort studies: childhood asthma. Eur. Respir. J. 27(Suppl.), 17S-22S (1998). (Pubitemid 28330818)
10. Masoli M, Fabian D, Holt S et al. The global burden of asthma: exec sum of the GINA dissemination committee report. Allergy 59, 469-478 (2004). (Pubitemid 38580764)
11. Benninger MS, Waters H. Montelukast: pharmacology, safety, tolerability and efficacy. Clin. Med. Ther. 1, 1253-1261 (2009).
12. Pawankar R. Allergic rhinitis and asthma: the link, the new ARIA classification and global approaches to treatment. Curr. Opin. All. Clin. Immunol. 4(1), 1-4 (2004). (Pubitemid 39090046)
13. Bousquet J, Demoly P, Humbert M. Montelukast in guidelines and beyond. Adv. Ther. 26(6), 575-587 (2009).
14. Cowie, RL, Underwood, MF, Feild SK. Inhaled CS therapy does not control asthma. Can. Respir. J. 11, 555-558 (2004). (Pubitemid 40089892)
15. Pajaron-Fernandez M, Garcia-Rubia S, Sanchez-Solis M et al. Montelukast administered in the morning or evening to prevent exercise-induced bronchoconstriction in children. Pediatr. Pulmonol. 41(3), 222-227 (2006).
16. Walia M, Lodha R, Kabra SK. Montelukast in pediatric asthma management. Indian J. Pediatr. 73(4), 276-282 (2006).
17. Cheng H, Leff JA, Amin R et al. Pharmacokinetics, bioavailability and safety of montelukast sodium (MK-0476) in healthy males and females. Pharm. Res. 13, 445-448 (1996). (Pubitemid 26114730)
18. Garcia ML, Wahn U, Gilles L et al. Montelukast, compared with fluticasone, for control of asthma among 6-to14 year-old patients with mild asthma: the MOSAIC study. Pediatrics 116(2), 360-369 (2005). (Pubitemid 44161461)
19. Ostrom NK, Decotiis BA, Lincourt WR et al. Comparative efficacy and safety of low-dose fluticasone proprionate and montelukast in children with persistent asthma. J. Pediatr. 147, 213-220 (2005). (Pubitemid 41207836)
20. Szelfer SJ, Phillips B, Martinez FD et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J. Allergy Clin. Immunol. 115, 592-597 (2005).
21. Sorkness CA, Lemanske RF, Mauger DT et al. Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial. J. Allergy Clin. Immunol. 119, 64-72 (2007). (Pubitemid 46043379)
22. Castro-Rodriguez JA, Rodrigo GJ. The role of inhaled corticosteroids and montelukast in children with mild- moderate asthma: systematic review with meta-analysis. Arch. Dis. Child. 95(5), 365-367 (2010).
23. Ducharme FM, di Salvio F. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst. Rev. 3, CD002314 (2000).
24. Ducharme FM. Inhaled glucocorticoids versus leukotrienes receptor antagonists as single agent asthma treatment: systematic review of current evidence. Br. Med. J. 326, 1-5 (2003).
25. Todd GR, Acerini CL, Ross-Russell R et al. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch. Dis. Child. 121, E1-E14 (2008).
26. Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N. Engl. J. Med. 343, 1064-1069 (2000).
27. Bisgaard H, Zielen S, Garcia-Garcia ML et al. Montelukast reduces asthma exacerbations in 2-to 5-year old children with intermittent asthma. Am. J. Respir. Crit. Care Med. 171, 315-322 (2005). (Pubitemid 40223397)
28. Bisgaard H. Randomized trial of montelukast in respiratory syncytial virus post-bronchiolitis. Am. J. Respir. Crit. Care Med. 167, 379-383 (2003). (Pubitemid 36216419)
29. Robertson CF, Price D, Henry R et al. Short course montelukast for intermittent asthma in children: a randomized controlled trial. Am. J. Respir. Crit. Care Med. 354, 1998-2005 (2006).
30. Johnston NW, Mandhane PJ, Dai J et al. Attenuation of the September epidemic of asthma exacerbations in children: a randomized controlled trial of montelukast added to usual therapy. Pediatrics 120(3), 3702-3712 (2007).
31. Weiss KB, Gern JE, Johnson NW et al. The back to school asthma study: the effect of montelukast on asthma burden when initiated prophylactically at the start of the school year. Ann. Allergy Asthma Immunol. 104(6), 511-517 (2010).
32. British Thoracic Society. Scottish Intercollegiate Guidelines Network. British guidelines on the management of asthma. Thorax 63(Suppl. 4), IV1-IV121 (2008).
33. Ducharme FM. Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma. Cochrane Database Syst. Rev. 3, CD003133 (2002).
34. Knorr B, Matz J, Bernstein JA et al. Montelukast for chronic asthma in 6-to 14-year old children: a randomized double-blind trial. Pediatric Montelukast Study Group. JAMA 279(15), 1181-1186 (1998).
35. Simons FE, Villa JR, Teper AM et al. Montelukast added to budesonide in children with persistent asthma. A randomized, double-blind, crossover study. J. Pediatr. 138(5), 694-698 (2001). (Pubitemid 32417670)
36. Jat GC, Mathew JL, Singh M. Treatment with 400 mcg of inhaled budesonide versus 200 mcg of inhaled budesonide and oral montelukast in children with moderate persistent asthma: a randomized control trial. Ann. Allergy Asthma Immunol. 97(3), 397-401 (2006). (Pubitemid 44476578)
37. Miraglia del Guidice M, Piacentini GL, Capasso M et al. Fomoterol, montelukast and budesonide in asthmatic children: effect on lung function and exhaled nitric oxide. Respir. Med. 101(8), 1809-1813 (2007). (Pubitemid 46930703)
38. Lemanske RF, Mauger DT, Sorkness CA et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N. Engl. J. Med. 362(11), 975-985 (2010).
39. Stelmach I, Korzeniewska A, Smejda K et al. Effect of montelukast on lung function and clinical symptoms in patients with cystic fibrosis. Pneumonol. Alergol. Pol. 72, 85-89 (2004). (Pubitemid 39093498)
40. Carraro S, Carradi M, Zanconato S et al. Exhaled breath condensate cysteinyl leukotrienes are increased in children with exercise-induced bronchoconstriction. J. Allergy Clin. Immunol. 115, 764-770 (2005). (Pubitemid 40460851)
41. Montuschi P, Mondino C, Koch P et al. Effects of a leukotriene receptor antagonist on exhaled leukotriene E4 and prostanoids in children with asthma. J. Allergy Clin. Immunol. 118, 347-353 (2006). (Pubitemid 44160715)
42. Fogul RB, Rosario N, Aristizabal G et al. Effect of montelukast or salmeterol added to inhaled fluticasone on exercise-induced bronchoconstriction in children. Ann. Allergy Asthma Immunol. 104(6), 511-517 (2010).
43. Wenzel SE. Antileukotriene drugs in the management of asthma. JAMA 280, 2068-2069 (1998). (Pubitemid 29014058)
44. Herland K, Akselsen JP, Skjonsberg OH et al. How representative are clinical study patients with asthma or COPD for a larger real life population of patients with obstructive lung disease? Respir. Med. 99, 11-19 (2005). (Pubitemid 40017378)
45. Dupont L, Potvin E, Korn D. Improving asthma control in patients suboptimally controlled on inhaled steroids and long acting b agonists: the addition of montelukast in an open-label pilot study. Curr. Med. Res. Opin. 21(6), 863-942 (2005).
46. Korn D, Van den Brande D, Potvin E et al. Efficacy of add-on montelukast in patients with non-controlled asthma: a Belgian open label study. Curr. Med. Res. Opin. 25(2), 489-497 (2009).
47. FitzGerald JM, Foucart S, Coyle S et al. Montelukast as add-on therapy to inhaled corticosteroids in the management of asthma (the SAS trial). Can. Respir. J. 16, 5A-14A (2009).
48. Virchow JC, Mehta A, Ljungblad L, Mitfessel H. Add-on montelukast in inadequately controlled asthma patients in a 6 month open label study: the montelukast in chronic asthma (MONICA) study. Respir. Med. 104(5), 644-651 (2010).
49. Schlick W, Pohl W, Pfeiffer KP et al. Evaluation of 3-5 months add-on therapy with montelukast in patients with non-controlled asthma in Austria: the STAR open-label, real world, observational study. Curr. Med. Res. Opin. 26(3), 561-570 (2010).
50. McIvor RA, Kaplan A, Koch C, Sampalis JS. Montelukast as an alternative to low-dose inhaled corticosteroids in the management of mild asthma (the SIMPLE trial): an open-label effectiveness trial. Can. Respir J. 16, 11A-21A (2009).
51. Keith PK, Koch C, Djandji M et al. Montelukast as add-on therapy with inhaled corticosteroids or inhaled corticosteroids and long acting b-2-agonist in the management of patients diagnosed with asthma and concurrent allergic rhinitis (the RADAR trail). Can. Respir. J. 16(Suppl. A), 17A-24A (2009).
52. Riccioni G, Bucciarelli T, Mancini B et al. Antileukotriene drugs: clinical application, effectiveness and safety. Curr. Med. Chem. 14, 1966-1977 (2007). (Pubitemid 47209107)
53. Wechsler ME, Finn D, Gunawardena D et al. Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest 117, 708-713 (2000). (Pubitemid 30152209)
54. Manalai P, Woo JM, Postolache TT. Suicidality and montelukast. Opin. Drug Saf. 8, 273-282 (2009).
55. Scadding GW, Scadding GK. Recent advances in antileukotriene therapy. Curr. Opin. Allergy Clin. 10(4), 370-376 (2010).
56. GINA: Global Initiative for Asthma http://ginasthma.com
57. Major accomplishments - Singulair www.merckfrosst.ca/mfcl/en/corporate/ research/accomplishments/singulair.html
58. US FDA - Drug Safety Information for Healthcare Professionals www.fda.gov/Drugs/DrugSafety/ PostMarketDrugS afetyInformationforPatientsandProviders/ DrugSafetyInformationfor HealthcareProfessionals/ucm165489.htm